GlassScriptPhysician profile
Patricia Kelly
NPI 1457518441
$982.71
in general payments reported to CMS, 2019-2025
14 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $134 · 2023: $295 · 2024: $268 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $207.27 | 2022-2025 | Breztri, Farxiga |
| Philips North America LLC | $177.58 | 2022-2025 | Mcot, (Ck4) Mcot, (5044) Mcot |
| Amgen INC. | $114.13 | 2022-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $105.24 | 2023-2025 | |
| Abiomed | $63.15 | 2024 | Impella |
| Lilly USA, LLC | $60.79 | 2023-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $43.87 | 2024-2025 | |
| Medicomp INC | $42.28 | 2024-2025 | Telepatch Cardiac Monitor |
| Novo Nordisk INC | $41.10 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $32.71 | 2025 | Assure Wcd |
| Abbott Laboratories | $26.27 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Merck Sharp & Dohme LLC | $24.95 | 2024 | Verquvo |
| Pfizer INC. | $22.46 | 2025 | |
| Baxter Healthcare | $20.91 | 2025 | Hillrom - Retinavue 700 Imager |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.